CartiHeal received FDA approval of its Investigational Device Exemption application submitted for the Agili-C™ implant, towards a Premarket Approval application.
The 2-year U.S./ex-U.S. pivotal study will involve a minimum of 250 patients, and seeks to show superiority of Agili-C vs. microfracture and debridement in the treatment of cartilage/osteochondral defects in osteoarthritic knees and in knees without degenerative changes. This marks the first approved study of broad indications using a single implant.
In early 1Q16, the company completed a US $15MM financing round to support manufacturing scale-up, EU product commercialization in 2017 and clinical studies in new therapeutic areas for Agili-C.
The investment was led by Johnson & Johnson Innovation and existing investors Elron, Accelmed, Access Medical Ventures and Peregrine Ventures.
Sources: CartiHeal, Ltd.; ORTHOWORLD Inc.
CartiHeal received FDA approval of its Investigational Device Exemption application submitted for the Agili-C™ implant, towards a Premarket Approval application.
The 2-year U.S./ex-U.S. pivotal study will involve a minimum of 250 patients, and seeks to show superiority of Agili-C vs. microfracture and debridement in the treatment of...
CartiHeal received FDA approval of its Investigational Device Exemption application submitted for the Agili-C™ implant, towards a Premarket Approval application.
The 2-year U.S./ex-U.S. pivotal study will involve a minimum of 250 patients, and seeks to show superiority of Agili-C vs. microfracture and debridement in the treatment of cartilage/osteochondral defects in osteoarthritic knees and in knees without degenerative changes. This marks the first approved study of broad indications using a single implant.
In early 1Q16, the company completed a US $15MM financing round to support manufacturing scale-up, EU product commercialization in 2017 and clinical studies in new therapeutic areas for Agili-C.
The investment was led by Johnson & Johnson Innovation and existing investors Elron, Accelmed, Access Medical Ventures and Peregrine Ventures.
Sources: CartiHeal, Ltd.; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.